AbbVie
ABBV
2,615 hedge funds and large institutions have $128B invested in AbbVie in 2021 Q1 according to their latest regulatory filings, with 152 funds opening new positions, 1,289 increasing their positions, 894 reducing their positions, and 101 closing their positions.
50% more first-time investments, than exits
New positions opened: 152 | Existing positions closed: 101
44% more repeat investments, than reductions
Existing positions increased: 1,289 | Existing positions reduced: 894
1% more funds holding
Funds holding: 2,599 → 2,615 (+16)
0% more capital invested
Capital invested by funds: $128B → $128B (+$46.6M)
0.63% less ownership
Funds ownership: 67.94% → 67.3% (-0.63%)
14% less call options, than puts
Call options by funds: $1.6B | Put options by funds: $1.85B
14% less funds holding in top 10
Funds holding in top 10: 161 → 138 (-23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$814M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$483M |
| 3 |
JP Morgan Chase
New York
|
+$355M |
| 4 |
Morgan Stanley
New York
|
+$256M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$245M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$1.89B |
| 2 |
Renaissance Technologies
New York
|
-$558M |
| 3 |
State Street
Boston,
Massachusetts
|
-$285M |
| 4 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$285M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$222M |
ABBV Hedge Fund Activity: Q1 2021 in Review
2,615 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2021, worth a combined $128B — up 0.04% from $128B a quarter earlier.
Buyers outnumbered sellers: 152 funds opened new ABBV positions and 101 closed out — a net gain of 51 holders — while 1,289 added to existing stakes and 894 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $814M. The largest seller was Capital Research Global Investors, cutting an estimated $1.89B.
- 2,615 institutional investors held AbbVie (ABBV) as of Q1 2021, up from 2,599 in Q4 2020.
- Funds reported $128B of AbbVie stock for Q1 2021, up 0.04% quarter-over-quarter.
- 152 funds opened new AbbVie positions in Q1 2021 and 101 closed out, a net change of +51 holders.
- The largest AbbVie buyer in Q1 2021 was Fidelity Investments, an estimated $814M added.
- The largest AbbVie seller in Q1 2021 was Capital Research Global Investors, an estimated $1.89B sold.
Based on aggregated 13F filings for Q1 2021.